EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fabry cardiomyopathy in Chinese populations: from the IVS4+919G>A founder variant to staged screening, diagnosis and management

Jianbin Chen, Liping Zheng, Zhiwei Wu, Junwei Huang, Min Cai, Jinzao Chen

Frontiers in Cardiovascular Medicine · 20.11.2026 · 13

DOI: 10.3389/fcvm.2026.1990333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 20.11.2026. Verfasst von Jianbin Chen und 5 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic GLA variants. Its cardiac form, which comprises left ventricular hypertrophy (LVH), fibrosis, heart failure and arrhythmia, accounts for most adult deaths. In Chinese-speaking populations, one late-onset splice variant, IVS4+919G>A, is strikingly common in Taiwanese newborn screening and in regional high-risk screening in eastern China. Its nationwide Mainland frequency, geographic spread and lifetime cardiac penetrance have never been measured. This review organises the field around the Nordin three-stage myocardial framework (storage, hypertrophy/inflammation, fibrosis) and prioritises Mainland Chinese and Taiwanese evidence. We searched PubMed, Embase, CNKI, Wanfang and journal websites (2000–2026; last search 4 September 2026) and appraised the cited studies in full, without formal systematic screening or meta-analysis; the search record is detailed in the Supplementary Material. Screening yield depends on the population tested: 0.88% (8/906) in a 55-centre Mainland unexplained-LVH cohort, 0.93% (2/217) in a Chinese hypertrophic cardiomyopathy (HCM) cohort, and 1.80% (7/388) in the Ninghai regional high-risk programme, against a pooled 1.2% internationally and about 1 in 1,600 male newborns in Taiwan. Cardiac magnetic resonance (CMR) shows low native T1 before LVH appears and late gadolinium enhancement (LGE) in the basal inferolateral mid-wall once fibrosis has formed; after LGE, disease-specific therapy becomes less effective. Screening for FD should therefore be routine in unexplained LVH/HCM in China. The pre-LGE treatment window is a hypothesis, not a rule. The cardiovascular evidence for disease-specific therapy is thin and needs prospective validation in Mainland Chinese and IVS4+919G>A cohorts. National registries, local reference thresholds and standardised follow-up are the clearest next steps.

Zitieren

APA

Chen, J., Zheng, L., Wu, Z., Huang, J., Cai, M., & Chen, J. (2026). Fabry cardiomyopathy in Chinese populations: from the IVS4+919G>A founder variant to staged screening, diagnosis and management. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1990333

Vancouver

Chen J, Zheng L, Wu Z, Huang J, Cai M, Chen J. Fabry cardiomyopathy in Chinese populations: from the IVS4+919G>A founder variant to staged screening, diagnosis and management. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1990333

BibTeX
@article{Chen2026,
  author = {Chen, Jianbin and Zheng, Liping and Wu, Zhiwei and Huang, Junwei and Cai, Min and Chen, Jinzao},
  title = {Fabry cardiomyopathy in Chinese populations: from the IVS4+919G>A founder variant to staged screening, diagnosis and management},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1990333}
}
Kostenlos starten →